Breaking Finance News

A statement released earlier today by Stifel Nicolaus about CoLucid Pharmaceuticals (NASDAQ:CLCD) bumps the target price to $30.00

Just yesterday CoLucid Pharmaceuticals (NASDAQ:CLCD) traded 5.28% higher at $28.13. CoLucid Pharmaceuticals’s 50-day moving average is $11.13 and its two hundred day moving average is $8.04. The last stock close is up 249.74% from the two hundred day moving average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Volume of trade was was up over the average, with 1,135,619 shares of CLCD changing hands over the typical 429,398 shares..

Stifel Nicolaus raised the target stock price of CoLucid Pharmaceuticals (NASDAQ:CLCD) to $30, stating a possible upside of 0.07%,

Performance Chart:

CoLucid Pharmaceuticals (NASDAQ:CLCD)

CoLucid Pharmaceuticals has a 52 week low of $3.57 and a one-year high of $28.44 and has a market capitalization of $0.0.

General Company Details For CoLucid Pharmaceuticals (NASDAQ:CLCD)

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, and placebo-controlled clinical trial of lasmiditan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *